Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer

Journal of Urology

Volumn 161, Issue 1, 1999, Pages 173-175

  Culine, S ^a,b   Kramar, A ^a   Droz, J P ^a   Theodore, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

Hormones; Prostatic neoplasms; Tretinoin

Indexed keywords

ANALGESIC AGENT; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; FEVER; HEADACHE; HORMONE RESISTANCE; HUMAN; LIP DISEASE; MALE; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; VOMITING;

EID: 0032862848     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62090-1     Document Type: Article

References (16)

1. Dawson, N. A.: Treatment of progressive metastatic prostate cancer. Oncology (Huntingt.), 7: 17, 1993.
2. Small, E. J. and Vogelzang, N. J.: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol., 15: 382, 1997.
3. Mani, S. and Vogelzang, N. J.: Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? Hematol. Oncol. N. Amer., 10: 749, 1996.
4. Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S. and Moinuddin, M.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61: 195, 1988.
5. Miller, A. B., Hoogstraten, B., Staquet, B. and Winkler, A.: Reporting results of cancer treatment. Cancer, 47: 207, 1981.
6. Smith, M. A., Parkinson, D. R., Cheson, B. D. and Friedman, M. A.: Retinoids in cancer therapy. J. Clin. Oncol., 10: 839, 1992.
7. Pollard, M., Luckert, P. H. and Sporn, M. B.: Prevention of primary prostate cancer in Lobund-Wistar rats by N(4-hydroxyphenyl)retinamide. Cancer Res., 51: 3610, 1991.
8. Pienta, K. J., Nguyen, N. M. and Lehr, J. E.: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res., 53: 224, 1993.
9. Higano, C. S. and Chielens, D.: α-interferon and cis-retinoic acid in combination for treatment of hormone-refractory prostate cancer: preliminary results of an ongoing trial. Proc. Amer. Soc. Clin. Oncol., 15: 243, 1996.
10. Kelly, W. K., Curley, T., Liebertz, C., Kim, B. and Scher, H.: Phase II trial of 13-cis-retinoic acid and interferon α2a in patients with adenocarcinoma of the prostate. Proc. Amer. Soc. Clin. Oncol., 15: 254, 1996.
11. Kelly, W. K., Scher, H. I., Muindi, J., Bajorin, D., O'Moore, P., Reuter, V., Young, C. W., Curley, T. and Liebertz, C.: Phase II of all-trans retinoic acid in patients with adenocarcinoma of the prostate. Proc. Amer. Assoc. Cancer Res., 34: 203, 1993.
12. Trump, D. L., Smith, D. C., Stiff, D., Adedoyin, A., Day, R., Bahnson, R. R., Hofacker, J. and Branch, R. A.: A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemother. Pharmacol., 39: 349, 1997.
13. Muindi, J., Frankel, S. R., Miller, W. H. Jr., Jakubowski, A., Scheinberg, D. A., Young, C. W., Dmitrovsky, E. and Warrell, R. P.: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood, 79: 299, 1992.
14. Smith, M. A., Adamson, P. C., Balis, F. M., Feusner, J., Aronson, L., Murphy, R. F., Horowitz, M. E., Reaman, G., Hammond, G. D., Fenton, R. M., Connaghan, G. D., Hittelman, W. N. and Poplack, D. G.: Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients with cancer. J. Clin. Oncol., 10: 1666, 1992.
15. Adamson, P. C., Boylan, J. F., Balis, F. M., Murphy, R. F., Godwin, K. A., Gudas, L. J. and Poplack, D. G.: Time course of induction of metabolism of all-trans retinoic acid and the upregulation of cellular retinoic acid-binding protein. Cancer Res., 53: 472, 1993.
16. Adamson, P. C., Bailey, J., Pluda, J., Poplack, D. G., Bauza, S., Murphy, R. F., Yarchoan, R. and Balis, F. M.: Pharmacokinetics of all-trans retinoic acid administered on an intermittent schedule. J. Clin. Oncol., 13: 1238, 1995.